Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04983264
Recruitment Status : Completed
First Posted : July 30, 2021
Last Update Posted : May 26, 2023
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Global Blood Therapeutics

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK), and pharmacodynamics (i.e., how the body absorbs, distributes, breaks down, and excretes) of GBT021601, a hemoglobin S (HbS) polymerization inhibitor, in participants with SCD, following single and multiple ascending doses.

Condition or disease Intervention/treatment Phase
Sickle Cell Disease Drug: GBT021601 Phase 1

Detailed Description:
This is an open-label intrapatient single dose followed by a multiple dose escalation study in at least six (6) participants with SCD.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Intrapatient Single Dose and Multiple Ascending Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of GBT021601, a Hemoglobin S Polymerization Inhibitor, in Participants With Sickle Cell Disease (SCD)
Actual Study Start Date : May 28, 2021
Actual Primary Completion Date : December 6, 2022
Actual Study Completion Date : December 12, 2022

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Single-dose Period (Part A)
Refer to Study Description
 Drug: GBT021601
Tablets and capsules which contain GBT021601 drug substance
Experimental: Multiple Ascending-dose Period (Part B and Part C)
Refer to Study Description
 Drug: GBT021601
Tablets and capsules which contain GBT021601 drug substance


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Safety, as assessed by frequency and severity of adverse events (AEs) [ Time Frame: 31 weeks ]
    AEs will be coded to system organ class and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA) and summarized.

  2. Safety, as assessed by changes in Heart Rate [ Time Frame: 31 weeks ]
    Number of participants with changes in heart rate (bpm) as compared to baseline

  3. Safety, as assessed by changes in QTcF [ Time Frame: 31 weeks ]
    Number of participants with changes in the QTcF interval from baseline

  4. Safety, as assessed by changes in eGFR [ Time Frame: 31 weeks ]
    Number of participants with changes in eGFR from baseline

  5. Safety, as assessed by changes in alanine aminotransferase (ALT) [ Time Frame: 31 weeks ]
    Number of participants with changes in alanine aminotransferase (ALT)

  6. Safety, as assessed by changes in Blood pressure [ Time Frame: 31 weeks ]
    Number of participants with changes in systolic (mmHg) and diastolic (mmHg) blood pressure from baseline


Secondary Outcome Measures :
  1. Determine plasma and whole blood concentrations of GBT021601 and calculate RBC concentrations. [ Time Frame: 31 weeks ]
    Noncompartmental PK analysis or population PK analysis using nonlinear mixed-effect modeling will be performed to characterize GBT021601 PK in plasma, and whole blood following single and multiple doses.

  2. Determine the pharmacodynamic effect of GBT021601 treatment. [ Time Frame: 14 weeks ]
    Hemoximetry will be used to assess oxygen saturation in whole blood by generating oxygen equilibrium curves (OECs) which relate the extent of Hb-O2 saturation to the partial pressure of O2 (pO2) and measure the binding affinity of O2 to Hb. Red Blood Cell Deformability will be measured by an Osmoscan. Individual and mean PD marker data will be presented graphically.

  3. To confirm the the relationship between time-matched GBT021601 concentrations and the change from baseline or percentage change from baseline of clinical measures of anemia and hemolysis. [ Time Frame: 14 weeks ]
    To confirm the correlation between time-matched GBT021601 concentrations and the change from baseline or percentage change from baseline of clinical measures of anemia (hemoglobin) and hemolysis (including indirect bilirubin, reticulocytes and lactate dehydrogenase).


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or Female with SCD
  • Participants with SCD ages 18 to 60 years, inclusive.
  • Participant has provided documented informed consent.
  • Patients with stable and close to baseline hemoglobin value
  • Patients on HU should be on stable dose for at least 90 days prior to signing ICF

Exclusion Criteria:

  • Patients had more than 10 VOC within 12 months of screening
  • Patients who are pregnant or nursing
  • Patients who receive RBC transfusion therapy regularly or received an RBC transfusion for any reason within 60 days of signing the ICF
  • Hospitalized for sickle cell crisis or other vaso-occlusive event within 14 days of signing the ICF or within 24 days prior to Day 1 treatment
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04983264


Locations
Layout table for location information
United States, Georgia
Visionaries Clinical Research
Atlanta, Georgia, United States, 30329
Children's Healthcare of Atlanta
Atlanta, Georgia, United States, 30342
Sponsors and Collaborators
Global Blood Therapeutics
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Global Blood Therapeutics
ClinicalTrials.gov Identifier: NCT04983264    
Other Study ID Numbers: GBT021601-012
C5351002 ( Other Identifier: Pfizer )
First Posted: July 30, 2021    Key Record Dates
Last Update Posted: May 26, 2023
Last Verified: May 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
 Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn